Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
Article in Molecular Cancer Therapeutics (December 2023)
The most recent citing publications are shown below. View all 79 publications that cite this research output on Dimensions.
Article in Molecular Cancer Therapeutics (December 2023)
Article in Journal of Biological Chemistry (July 2023)
Article in Cancers (June 2023)